We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma
News

MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma

MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma
News

MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that Bayer Schering Pharma AG, Germany has filed all necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived antibody-drug conjugate (ADC) in the therapeutic area of oncology. This achievement marks a significant milestone within the Bayer Schering Pharma alliance and triggers a payment to MorphoSys.

"Today's news underlines how important our core technology is to the pharmaceutical industry's drug pipeline," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "We now have clinical trials of HuCAL-based antibodies ongoing with four different pharmaceutical companies. The output of our partners' application of MorphoSys's proprietary HuCAL technology is becoming an increasingly visible and important value driver for our Company."

The current program is directed against the target molecule MN, also known as Carbonic Anhydrase or CA IX for short, a tumor associated antigen expressed in many tumor types under hypoxic conditions. The antibody is the first fully human HuCAL-based ADC to enter clinical trials.

ADCs comprise antibodies linked to cytotoxic drugs, and combine the targeting properties of the antibody with the cell-destroying effect of the conjugated drug. In the present program, the HuCAL-derived antibody-drug conjugate incorporates technology licensed to Bayer Schering Pharma from Seattle Genetics.
Advertisement